Abstract
Lymph nodes (LNs) are the quintessential organs of immunity. Our understanding of how LNs control
alloimmune responses has evolved significantly with recent advances which highlight the function of specific
cellular and stromal components of the LN. Presentation of donor alloantigen to recipient T cells in the LN is
fundamental to the priming of allo-reactive T cells and subsequent allograft rejection. A recently recognized,
new dimension to this pervasive concept is that the LN is also critically important for transplant tolerance.
These multifaceted functions reflect the status of LNs as extremely specialized organs with unique
microvasculature, and a stromal compartment that is molded and regulated by resident mesenchymal cells
known as fibroblastic reticular cells (FRCs). The overall hypothesis of this project is that sustained activation
of FRCs in the draining LN (DLN) following transplantation results in their transformation to scar-forming pro-
inflammatory myofibroblasts, which further promote alloimmunity. Our studies will focus mechanistically on the
importance of the LIGHT/HVEM signaling pathway to the differentiation of FRCs into proinflammatory
myofibroblasts in the LN following transplantation. Our corollary hypothesis is that restoration of the native
function of FRCs through targeted drug delivery to LNs will enhance their immunoregulatory function and
promote tolerance. We are proposing three AIMS as follows: In AIM 1, we will examine the role of the
LIGHT/HVEM pathway in regulating the function of FRCs, controlling extracellular matrix (ECM) accumulation,
and mediating transplant immunity. Using global LIGHT and HVEM knockout mice, and mice with conditional
knockout of HVEM on FRCs, we will gain mechanistic insights into how the LIGHT/HVEM pathway controls the
differentiation of FRCs and transplantation outcomes. In AIM 2, we will study the importance of senescence in
determining the balance between the pro-inflammatory and anti-inflammatory properties of FRCs. We will use
a number of innovative conditional knockout mice to decipher the mechanisms by which senescent FRCs
promote alloimmunity following transplantation. In AIM 3, we will determine whether delivering healthy FRCs
and senolytic agents to the DLN will restore its microarchitecture and regulate alloimmunity following
transplantation. The data from these studies will lay the groundwork for the first time to develop innovative
therapeutic strategies aimed at manipulating the microenvironment within LNs. This provides a unique
opportunity to direct the alloimmune response following transplantation towards tolerance. This proposal
establishes a multidisciplinary collaborative team to produce novel mechanistic data, which will provide the
basis for highly innovative and selective therapeutic strategies for transplantation. Therefore, this proposal can
make transformative advances in the field of organ transplantation.
Public Health Relevance Statement
Public Health Relevance Statement
Organ transplantation is a gold standard treatment that has saved the lives of patients with irreversible organ
damage. The goal of this proposal is to generate highly innovative data that will address the key unmet clinical
need to devise highly specific, targeted immune therapies for transplantation.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
030811269
UEI
QN6MS4VN7BD1
Project Start Date
27-July-2020
Project End Date
30-June-2025
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$511,721
Direct Costs
$300,000
Indirect Costs
$211,721
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$511,721
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI153003-05 6327
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI153003-05 6327
Patents
No Patents information available for 5P01AI153003-05 6327
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI153003-05 6327
Clinical Studies
No Clinical Studies information available for 5P01AI153003-05 6327
News and More
Related News Releases
No news release information available for 5P01AI153003-05 6327
History
No Historical information available for 5P01AI153003-05 6327
Similar Projects
No Similar Projects information available for 5P01AI153003-05 6327